当前位置: 首页 >> 检索结果
181. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
作者: Frederick Raal.;Ronen Durst.;Ran Bi.;Zsolt Talloczy.;Pierre Maheux.;Anastasia Lesogor.;John J P Kastelein.; .
来源: Circulation. 2024年149卷5期354-362页
Homozygous familial hypercholesterolemia is a genetic disease characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature cardiovascular events. The proof-of-concept study ORION-2 (A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia) showed that inclisiran, a small interfering RNA that prevents production of the hepatic PCSK9 protein (proprotein convertase subtilisin/kexin type 9), could lead to durable reductions in LDL-C levels when added to statins and ezetimibe in patients with homozygous familial hypercholesterolemia.
182. Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
作者: Denis J Wakeham.;Erika Ivey.;Sophie A Saland.;Joshua S Lewis.;Dean Palmer.;Margot Morris.;Jeffery L Bleich.;Peter G Weyand.;Tiffany L Brazile.;Christopher M Hearon.;Satyam Sarma.;James P MacNamara.;Michinari Hieda.;Benjamin D Levine.
来源: Circulation. 2023年148卷25期2008-2016页
Despite advances in medical and cardiac resynchronization therapy (CRT), individuals with chronic congestive heart failure (CHF) have persistent symptoms, including exercise intolerance. Optimizing cardio-locomotor coupling may increase stroke volume and skeletal muscle perfusion as previously shown in healthy runners. Therefore, we tested the hypothesis that exercise stroke volume and cardiac output would be higher during fixed-paced walking when steps were synchronized with the diastolic compared with systolic portion of the cardiac cycle in patients with CHF and CRT.
183. Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVR III Study.
作者: Caren S Goldberg.;Felicia Trachtenberg.;J William Gaynor.;William T Mahle.;Chitra Ravishankar.;Steven M Schwartz.;James F Cnota.;Richard G Ohye.;Russell Gongwer.;Michael Taylor.;Stephen Paridon.;Peter C Frommelt.;Katherine Afton.;Andrew M Atz.;Kristin M Burns.;Jon A Detterich.;Kevin D Hill.;Antonio G Cabrera.;Alan B Lewis.;Christian Pizarro.;Amee Shah.;Binu Sharma.;Jane W Newburger.; .
来源: Circulation. 2023年148卷17期1330-1339页
In the SVR trial (Single Ventricle Reconstruction), newborns with hypoplastic left heart syndrome were randomly assigned to receive a modified Blalock-Taussig-Thomas shunt (mBTTS) or a right ventricle-to-pulmonary artery shunt (RVPAS) at Norwood operation. Transplant-free survival was superior in the RVPAS group at 1 year, but no longer differed by treatment group at 6 years; both treatment groups had accumulated important morbidities. In the third follow-up of this cohort (SVRIII [Long-Term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type]), we measured longitudinal outcomes and their risk factors through 12 years of age.
184. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial.
作者: Novalia P Sidik.;Bethany Stanley.;Robert Sykes.;Andrew J Morrow.;Conor P Bradley.;Michael McDermott.;Thomas J Ford.;Giles Roditi.;Allister Hargreaves.;David Stobo.;Jacqueline Adams.;John Byrne.;Ahmed Mahrous.;Robin Young.;David Carrick.;Ross McGeoch.;David Corcoran.;Ninian N Lang.;Robert Heggie.;Olivia Wu.;Margaret B McEntegart.;Alex McConnachie.;Colin Berry.
来源: Circulation. 2024年149卷1期7-23页
We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries.
185. Blood Pressure and Oxygen Targets on Kidney Injury After Cardiac Arrest.
作者: Sebastian Buhl Rasmussen.;Karoline Korsholm Jeppesen.;Jesper Kjaergaard.;Christian Hassager.;Henrik Schmidt.;Simon Mølstrøm.;Rasmus Paulin Beske.;Johannes Grand.;Hanne Berg Ravn.;Matilde Winther-Jensen.;Martin Abild Stengaard Meyer.;Jacob Eifer Møller.
来源: Circulation. 2023年148卷23期1860-1869页
Acute kidney injury (AKI) represents a common and serious complication to out-of-hospital cardiac arrest. The importance of post-resuscitation care targets for blood pressure and oxygenation for the development of AKI is unknown.
186. Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial.
作者: Daniel A Jones.;Anne-Marie Beirne.;Matthew Kelham.;Krishnaraj S Rathod.;Mervyn Andiapen.;Lucinda Wynne.;Thomas Godec.;Nasim Forooghi.;Rohini Ramaseshan.;James C Moon.;Ceri Davies.;Christos V Bourantas.;Andreas Baumbach.;Charlotte Manisty.;Andrew Wragg.;Amrita Ahluwalia.;Francesca Pugliese.;Anthony Mathur.; .
来源: Circulation. 2023年148卷18期1371-1380页
Patients with previous coronary artery bypass grafting often require invasive coronary angiography (ICA). However, for these patients, the procedure is technically more challenging and has a higher risk of complications. Observational studies suggest that computed tomography cardiac angiography (CTCA) may facilitate ICA in this group, but this has not been tested in a randomized controlled trial.
187. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
作者: Peter A Henriksen.;Peter Hall.;Iain R MacPherson.;Shruti S Joshi.;Trisha Singh.;Morag Maclean.;Steff Lewis.;Aryelly Rodriguez.;Alex Fletcher.;Russell J Everett.;Harriet Stavert.;Angus Broom.;Lois Eddie.;Lorraine Primrose.;Heather McVicars.;Pam McKay.;Annabel Borley.;Clare Rowntree.;Simon Lord.;Graham Collins.;John Radford.;Amy Guppy.;Michelle C Williams.;Alan Japp.;John R Payne.;David E Newby.;Nicholas L Mills.;Olga Oikonomidou.;Ninian N Lang.
来源: Circulation. 2023年148卷21期1680-1690页
Anthracycline-induced cardiotoxicity has a variable incidence, and the development of left ventricular dysfunction is preceded by elevations in cardiac troponin concentrations. Beta-adrenergic receptor blocker and renin-angiotensin system inhibitor therapies have been associated with modest cardioprotective effects in unselected patients receiving anthracycline chemotherapy.
188. Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial.
作者: Zardasht Oqab.;Vijay Kunadian.;David A Wood.;Robert F Storey.;Sunil V Rao.;Roxana Mehran.;Natalia Pinilla-Echeverri.;Thenmozhi Mani.;Robert H Boone.;Saleem Kassam.;Matthias Bossard.;Samer Mansour.;Warren Ball.;Matthew Sibbald.;Nicholas Valettas.;Raul Moreno.;Philippe Gabriel Steg.;John A Cairns.;Shamir R Mehta.
来源: Circ Cardiovasc Interv. 2023年16卷9期e012867页
In the COMPLETE trial (Complete Versus Culprit-Only Revascularization to Treat Multivessel Disease After Early PCI for STEMI), a strategy of complete revascularization reduced the risk of major cardiovascular events compared with culprit-lesion-only percutaneous coronary intervention in patients presenting with ST-segment-elevation myocardial infarction (STEMI) and multivessel coronary artery disease. Patients with diabetes have a worse prognosis following STEMI. We evaluated the consistency of the effects of complete revascularization in patients with and without diabetes.
189. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
作者: Derek S Chew.;Yanhong Li.;Robert Bigelow.;Patricia A Cowper.;Kevin J Anstrom.;Melanie R Daniels.;Linda Davidson-Ray.;Adrian F Hernandez.;Christopher M O'Connor.;Paul W Armstrong.;Daniel B Mark.; .
来源: Circulation. 2023年148卷14期1087-1098页
The VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) demonstrated that, in patients with high-risk heart failure, vericiguat reduced the primary composite outcome of cardiovascular death or heart failure hospitalization relative to placebo. The hazard ratio for all-cause mortality was 0.95 (95% CI, 0.84-1.07). In a prespecified analysis, treatment effects varied substantially as a function of baseline NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, with survival benefit for vericiguat in the lower NT-proBNP quartiles (hazard ratio, 0.82 [95% CI, 0.69-0.97]) and no benefit in the highest NT-proBNP quartile (hazard ratio, 1.14 [95% CI, 0.95-1.38]). An economic analysis was a major secondary objective of the VICTORIA research program.
190. Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
作者: Yugo Yamashita.;Takeshi Morimoto.;Nao Muraoka.;Takuya Oyakawa.;Michihisa Umetsu.;Daijirou Akamatsu.;Yuji Nishimoto.;Yukihito Sato.;Takuma Takada.;Kentaro Jujo.;Yuichiro Minami.;Yoshito Ogihara.;Kaoru Dohi.;Masashi Fujita.;Tatsuya Nishikawa.;Nobutaka Ikeda.;Go Hashimoto.;Kazunori Otsui.;Kenta Mori.;Daisuke Sueta.;Yukari Tsubata.;Masaaki Shoji.;Ayumi Shikama.;Yutaka Hosoi.;Yasuhiro Tanabe.;Ryuki Chatani.;Kengo Tsukahara.;Naohiko Nakanishi.;Kitae Kim.;Satoshi Ikeda.;Makoto Mo.;Yusuke Yoshikawa.;Takeshi Kimura.; .
来源: Circulation. 2023年148卷21期1665-1676页
The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding.
191. Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement: A Randomized, Open-Label, Noninferiority Trial.
作者: Martin Reindl.;Ivan Lechner.;Magdalena Holzknecht.;Christina Tiller.;Priscilla Fink.;Fritz Oberhollenzer.;Sebastian von der Emde.;Mathias Pamminger.;Felix Troger.;Christian Kremser.;Elisabeth Laßnig.;Kathrin Danninger.;Ronald K Binder.;Hanno Ulmer.;Christoph Brenner.;Gert Klug.;Axel Bauer.;Bernhard Metzler.;Agnes Mayr.;Sebastian J Reinstadler.
来源: Circulation. 2023年148卷16期1220-1230页
Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, a sizable proportion of TAVR candidates have chronic kidney disease, in whom the use of iodinated contrast media is a limitation. Cardiac magnetic resonance imaging (CMR) is a promising alternative, but randomized data comparing the effectiveness of CMR-guided versus CT-guided TAVR are lacking.
192. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
作者: Linda P T Joosten.;Sander van Doorn.;Peter M van de Ven.;Bart T G Köhlen.;Melchior C Nierman.;Huiberdina L Koek.;Martin E W Hemels.;Menno V Huisman.;Marieke Kruip.;Laura M Faber.;Nynke M Wiersma.;Wim F Buding.;Rob Fijnheer.;Henk J Adriaansen.;Kit C Roes.;Arno W Hoes.;Frans H Rutten.;Geert-Jan Geersing.
来源: Circulation. 2024年149卷4期279-289页
There is ambiguity whether frail patients with atrial fibrillation managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC).
193. Optical Coherence Tomography-Guided or Intravascular Ultrasound-Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial.
作者: Do-Yoon Kang.;Jung-Min Ahn.;Sung-Cheol Yun.;Seung-Ho Hur.;Yun-Kyeong Cho.;Cheol Hyun Lee.;Soon Jun Hong.;Subin Lim.;Sang-Wook Kim.;Hoyoun Won.;Jun-Hyok Oh.;Jeong Cheon Choe.;Young Joon Hong.;Yong-Hoon Yoon.;Hoyun Kim.;Yeonwoo Choi.;Jinho Lee.;Young Won Yoon.;Soo-Joong Kim.;Jang-Ho Bae.;Duk-Woo Park.;Seung-Jung Park.; .
来源: Circulation. 2023年148卷16期1195-1206页
Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared with angiography-guided PCI. However, the comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown.
194. Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.
作者: Marco Valgimigli.;Adrian Wlodarczak.;Ralph Tölg.;Béla Merkely.;Henning Kelbæk.;Jacek Legutko.;Stefano Galli.;Matthieu Godin.;Gabor G Toth.;Thibault Lhermusier.;Benjamin Honton.;Peter Laurenz Dietrich.;Francis Stammen.;Bert Ferdinande.;Johanne Silvain.;Davide Capodanno.;Guillaume Cayla.; .
来源: Circulation. 2023年148卷13期989-999页
Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbreviated dual antiplatelet therapy duration after percutaneous coronary intervention (PCI). The aim of this study was to compare the safety and effectiveness of the biodegradable-polymer sirolimus-eluting stent with the durable-polymer zotarolimus-eluting stent in patients at high bleeding risk receiving 1 month of dual antiplatelet therapy after PCI.
195. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
作者: Milton Packer.;Javed Butler.;Cordula Zeller.;Stuart J Pocock.;Martina Brueckmann.;João Pedro Ferreira.;Gerasimos Filippatos.;Muhammad Shariq Usman.;Faiez Zannad.;Stefan D Anker.
来源: Circulation. 2023年148卷13期1011-1022页
It is not known whether the benefits of sodium-glucose cotransporter 2 inhibitors in heart failure persist after years of therapy.
196. Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial.
作者: Frederik M Zimmermann.;Victoria Y Ding.;Nico H J Pijls.;Zsolt Piroth.;Albert H M van Straten.;Laszlo Szekely.;Giedrius Davidavicius.;Gintaras Kalinauskas.;Samer Mansour.;Rajesh Kharbanda.;Nikolaos Östlund-Papadogeorgos.;Adel Aminian.;Keith G Oldroyd.;Nawwar Al-Attar.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Oskar Angeras.;Philip MacCarthy.;Olaf Wendler.;Filip Casselman.;Nils Witt.;Kreton Mavromatis.;Steven E S Miner.;Jaydeep Sarma.;Thomas Engstrøm.;Evald H Christiansen.;Pim A L Tonino.;Michael J Reardon.;Hisao Otsuki.;Yuhei Kobayashi.;Mark A Hlatky.;Kenneth W Mahaffey.;Manisha Desai.;Y Joseph Woo.;Alan C Yeung.;Bernard De Bruyne.;William F Fearon.; .
来源: Circulation. 2023年148卷12期950-958页
Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI.
197. Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial.
作者: Divaka Perera.;Holly P Morgan.;Matthew Ryan.;Matthew Dodd.;Tim Clayton.;Peter D O'Kane.;John P Greenwood.;Simon J Walsh.;Roshan Weerackody.;Adam McDiarmid.;George Amin-Youssef.;Julian Strange.;Bhavik Modi.;Timothy Lockie.;Kai Hogrefe.;Fozia Z Ahmed.;Miles Behan.;Nicholas Jenkins.;Eltigani Abdelaal.;Michelle Anderson.;Stuart Watkins.;Richard Evans.;Christopher A Rinaldi.;Mark C Petrie.; .
来源: Circulation. 2023年148卷11期862-871页
Ventricular arrhythmia is an important cause of mortality in patients with ischemic left ventricular dysfunction. Revascularization with coronary artery bypass graft or percutaneous coronary intervention is often recommended for these patients before implantation of a cardiac defibrillator because it is assumed that this may reduce the incidence of fatal and potentially fatal ventricular arrhythmias, although this premise has not been evaluated in a randomized trial to date.
198. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
作者: Barry A Borlaug.;Yogesh N V Reddy.;Amanda Braun.;Hidemi Sorimachi.;Massar Omar.;Dejana Popovic.;Alessio Alogna.;Michael D Jensen.;Rickey Carter.
来源: Circulation. 2023年148卷10期834-844页
Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits remain unclear. This study sought to determine whether treatment with dapagliflozin affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in patients with HFpEF.
199. DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients With Heart Failure With Reduced Ejection Fraction.
作者: Aradhana Verma.;Gregg C Fonarow.;Jeffrey J Hsu.;Cynthia A Jackevicius.;Freny Vaghaiwalla Mody.;Amanda Nguyen.;Omid Amidi.;Sarah Goldberg.;Reeta Vetrivel.;Deepti Upparapalli.;Kleanthis Theodoropoulos.;Stephanie Gregorio.;Donald S Chang.;Kristina Bostrom.;Andrew D Althouse.;Boback Ziaeian.
来源: Circ Heart Fail. 2023年16卷9期e010278页
Heart failure is a prevailing diagnosis of hospitalization and readmission within 6 months, and nearly a quarter of these patients die within a year. Guideline-directed medication therapies reduce risk of mortality by 73% over 2 years; however, the implementation of these therapies to their target dose in clinical practice continues to be challenging. In 2020, the Veterans Affairs (VA) Health Care System developed a HF dashboard to monitor and improve outpatient HF management. The DASH-HF (Dashboard Activated Services and Telehealth for Heart Failure) study is a randomized, pragmatic clinical trial to evaluate proactive dashboard-directed telehealth clinics to improve the use and dosing of guideline-directed medication therapy for patients with heart failure with reduced ejection fraction not on optimal guideline-directed medication therapy within the VA.
200. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.
作者: Frans Van de Werf.;Arsen D Ristić.;Oleg V Averkov.;Alexandra Arias-Mendoza.;Yves Lambert.;José F Kerr Saraiva.;Pablo Sepulveda.;Fernando Rosell-Ortiz.;John K French.;Ljilja B Musić.;Katleen Vandenberghe.;Kris Bogaerts.;Cynthia M Westerhout.;Alain Pagès.;Thierry Danays.;Kevin R Bainey.;Peter Sinnaeve.;Patrick Goldstein.;Robert C Welsh.;Paul W Armstrong.; .
来源: Circulation. 2023年148卷9期753-764页
ST-segment-elevation myocardial infarction (STEMI) guidelines recommend pharmaco-invasive treatment if timely primary percutaneous coronary intervention (PCI) is unavailable. Full-dose tenecteplase is associated with an increased risk of intracranial hemorrhage in older patients. Whether pharmaco-invasive treatment with half-dose tenecteplase is effective and safe in older patients with STEMI is unknown.
|